News
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
And more pharma news updates from Pharmalittle.
Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results